Center for Stem Cell and Regenerative Medicine, Department of Pharmacology, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.
Center for Stem Cell and Regenerative Medicine, Department of Pharmacology, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.
Trends Cell Biol. 2018 Dec;28(12):987-998. doi: 10.1016/j.tcb.2018.05.003. Epub 2018 May 29.
The hematopoietic stem cell (HSC) niche supports steady-state hematopoiesis and responds to changing needs during stress and disease. The nervous system is an important regulator of the niche, and its influence is established early in development when stem cells are specified. Most research has focused on direct innervation of the niche, however recent findings show there are different modes of neural control, including globally by the central nervous system (CNS) and hormone release, locally by neural crest-derived mesenchymal stem cells, and intrinsically by hematopoietic cells that express neural receptors and neurotransmitters. Dysregulation between neural and hematopoietic systems can contribute to disease, however new therapeutic opportunities may be found among neuroregulator drugs repurposed to support hematopoiesis.
造血干细胞 (HSC) 龛位支持稳态造血,并在应激和疾病期间响应不断变化的需求。神经系统是龛位的重要调节剂,其影响在干细胞被指定时就已在早期发育中确立。大多数研究都集中在龛位的直接神经支配上,然而最近的发现表明存在不同的神经控制模式,包括中枢神经系统 (CNS) 和激素释放的全局控制、神经嵴衍生的间充质干细胞的局部控制以及表达神经受体和神经递质的造血细胞的内在控制。神经和造血系统之间的失调可能导致疾病,但是可以在重新用于支持造血的神经调节剂药物中找到新的治疗机会。